The major NCI SBIR & STTR portfolio areas are listed below as a guide to general technology areas funded through the program. Applications proposing innovative cancer-related technologies, with strong commercial potential, that fall outside these topic areas are also welcomed through the Omnibus Solicitation.
Major NCI SBIR & STTR Portfolio Areas
- Therapeutics (e.g., Small Molecules, Biologics, Radiomodulators, and Cell-based Therapies)
- In Vitro and In Vivo Diagnostics (e.g., Companion Diagnostics and Prognostic Technologies)
- Imaging Technologies (e.g., Agents, Devices, and Image-Guided Interventions)
- Devices for Cancer Therapy (e.g., Interventional Devices, Surgical, Radiation and Ablative Therapies)
- Tools for Cancer Biology Research
- Technologies and Agents for Cancer Prevention
- Technologies for Cancer Control (e.g., Behavioral Health Interventions, Tools for Genetic, Epidemiologic, Behavioral, Social, and/or Surveillance Cancer Research)
- Digital Health (e.g., Mobile Health, Health Information Technology, and Bioinformatics)
NCI particularly encourages applications in the following current research topics of interest:
- Vaccine Development for Cancer Prevention
- Novel Technologies to Address “Undruggable” Drug Targets
- Automated Methods for Extraction and Consolidation of Cancer Registry Data
- Development of Novel Cancer Therapeutics Targeting Epigenetic Alterations
- Integrated Image-Guided Biopsy Platforms for Assessing Tumor Tissue Heterogeneity
- Development and Commercialization of Technologies in Quantitative Imaging of Cancer to Evaluate or Predict Response to Therapy
- Machine Learning Software Tools to Quantify Cancer Radiation Therapy’s Effects on Tumors and Normal Tissue
- Software Tools to Measure the Volume, Type, and Quality of Cancer Patient Care
- Molecularly Targeted Therapies, Immunotherapies, or Other Specialized Treatments for Pediatric Oncology (Childhood Cancers)
- Novel Software Tools that Increase the Speed of Data Aggregation Across Diverse Scientific and Clinical Datasets
NCI accepts and encourages SBIR & STTR applications to support clinical trials.